药品注册申请号:213725
申请类型:ANDA (仿制药申请)
申请人:SUN PHARM
申请人全名:SUN PHARMACEUTICAL INDUSTRIES LTD
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 PANTOPRAZOLE SODIUM PANTOPRAZOLE SODIUM FOR SUSPENSION, DELAYED RELEASE;ORAL EQ 40MG BASE No No AB 2020/06/30 2020/06/30 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2023/11/29 SUPPL-6(补充) Approval Labeling STANDARD
2022/09/27 SUPPL-4(补充) Approval Labeling STANDARD
2021/06/04 SUPPL-1(补充) Approval Labeling STANDARD
2020/06/30 ORIG-1(原始申请) Approval STANDARD
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
001 PC 2021/02/09**本条是由Drugfuture回溯的历史信息**
与本品治疗等效的药品
活性成分:PANTOPRAZOLE SODIUM 剂型/给药途径:FOR SUSPENSION, DELAYED RELEASE;ORAL 规格:EQ 40MG BASE 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
022020 001 NDA PROTONIX PANTOPRAZOLE SODIUM FOR SUSPENSION, DELAYED RELEASE;ORAL EQ 40MG BASE Prescription Yes Yes AB 2007/11/14 WYETH PHARMS
213725 001 ANDA PANTOPRAZOLE SODIUM PANTOPRAZOLE SODIUM FOR SUSPENSION, DELAYED RELEASE;ORAL EQ 40MG BASE Prescription No No AB 2020/06/30 SUN PHARM
217416 001 ANDA PANTOPRAZOLE SODIUM PANTOPRAZOLE SODIUM FOR SUSPENSION, DELAYED RELEASE;ORAL EQ 40MG BASE Prescription No No AB 2023/02/09 AJANTA PHARMA LTD
216247 001 ANDA PANTOPRAZOLE SODIUM PANTOPRAZOLE SODIUM FOR SUSPENSION, DELAYED RELEASE;ORAL EQ 40MG BASE Prescription No No AB 2023/06/16 DEXCEL
216139 001 ANDA PANTOPRAZOLE SODIUM PANTOPRAZOLE SODIUM FOR SUSPENSION, DELAYED RELEASE;ORAL EQ 40MG BASE Prescription No No AB 2023/10/27 ANNORA PHARMA
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database